Umpierrez GE, Cardona S, Chachkhiani D et al (2018) A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC trial
Amylin (also called islet amyloid polypeptide, or IAPP) is a 37-amino acid peptide hormone co-secreted by the beta cells of the pancreas alongside insulin, typically in response to meals
Within controlled research settings, this compound is often associated with improved sleep quality and higher daily energy levels
To study combined effects on collagen synthesis, angiogenesis, cell migration, and inflammation in one protocol
The 4.5 mg dose produced 10.8% mean weight loss at 26 weeks
The final section of this review synthesizes these insights into a forward-looking perspective on the future of peptide therapeutics and articulates why the rediscovery of dormant biology, when guided by modern pharmacologic principles, may represent the most productive frontier in drug discovery